Disulfide compound and application thereof in preparation of medicine for preventing and / or treating bacterial diseases
By developing disulfide ethers used to inhibit bacterial group sensing systems, the problem of bacterial disease prevention and control in the prior art was solved, effective inhibition of Pseudomonas aeruginosa, Cyclotridium and Phytomonas aeruginosa was achieved, and the drugs were extended The life span of use and reduces the resistance of pathogens.
Patent Information
- Application Number
- CN202410907260.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-08
- Publication Date
- 2024-11-15
AI Technical Summary
The lack of effective bacterial population sensing system inhibitors in the prior art makes it difficult to effectively prevent and treat diseases caused by Pseudomonas aeruginosa, Cyperus and Thalassia, and pathogens are resistant to antibiotics.
A novel disulfide and its pharmaceutically acceptable salt have been developed to significantly reduce its pathogenicity and delay drug resistance production by inhibiting the population sensing system of pathogens.
This disulfide can significantly inhibit its pathogenicity without affecting the growth of pathogenic bacteria, extend the effective use period of the drug, and show an inhibitory effect better than that of positive control drugs, against Pseudomonas aeruginosa, Cyclotridium et al. Thermomonas has significant antibacterial activity.
Smart Images

Figure CN118955342A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of bacterial disease prevention and treatment, and more specifically, relates to a disulfide compound and its application in preparing a drug for preventing and / or treating bacterial diseases. Background Art
[0002] Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative bacterium that is commonly found in various environments, including water, air, soil, plants and animals. It is also found in the skin, intestines and respiratory tract of normal people. After infecting the host, P. aeruginosa releases a variety of virulence factors, including exoenzymes, pyocyanin, elastase and hemolysin, which cause complex pathological changes in the host. P. aeruginosa coordinates some important functions related to pathogenicity through the QS system, including biofilm formation, immune response regulation, swarming movement, and the production of exopolysaccharides and toxins. Quorum sensing regulates the expression of about 60% of the pathogenic genes of P. aeruginosa. It is known that Pseudomonas aeruginosa has four quorum sensing systems, including the las system and rhl system mediated by AHLs signals, the pqs system mediated by quinolone (PQS) signals, and the recently discovered iqs system with 2-(2-hydroxyphenyl)-thiazolyl-4-carboxaldehyde (Integrated Quorum Sensing Signal, IQS) as the signal molecule. Currently, Pseudomonas aeruginosa shows a certain degree of resistance to a variety of antibiotics. Therefore, the development of Pseudomonas aeruginosa QS system inhibitors is an effective way to improve its resistance and effectively prevent and treat infections caused by it.
[0003] Ralstonia solanacearum, also known as Ralstonia solanacearum, is a widely distributed and seriously harmful Gram-negative soil plant pathogen that causes major damage worldwide. Ralstonia solanacearum thrives in the xylem vessels of host plants. Ralstonia solanacearum colonizes in the xylem vessels of host plants and blocks the vessels from transporting nutrients such as water and inorganic salts upward, causing the host plants to wilt or even die. The pathogenicity of Ralstonia solanacearum is determined by multiple virulence factors such as extracellular polysaccharides (EPSs), extracellular proteins (EXPs), motility, biofilm and T3SS. Type III secretion systems (T3SS) are very conservative and key virulence factors in Gram-negative pathogenic bacteria, but they are not the most critical factor for bacterial growth. This feature makes T3SS an ideal target for the development of new antimicrobial drugs. Screening inhibitors against T3SS, clarifying their inhibitory effects, and elucidating their inhibitory mechanisms will provide direction for the formulation of new bacterial wilt prevention and control measures oriented towards interfering with T3SS in the future.
[0004] Rice bacterial blight is an important bacterial disease of rice, caused by Xanthomonas oryzae pv.oryzae (Xoo). It first occurred in Fukuoka Prefecture, Japan, and was first discovered in Nanjing, my country in 1950. It has now become one of the major diseases that harm the main rice producing areas in Asia. Xoo can infect rice throughout the growth period, and invades the host through mechanical wounds, insect bites or natural holes, which are usually located at the edge of the leaf. The bacteria then multiply in the intercellular spaces of the parenchyma, eventually infecting the xylem vessels of the host and spreading to other parts. In the early stage of infection, water-soaked yellow-green chlorotic spots appear. As the disease progresses, the spots gradually become more serious, and the spots expand from the tip of the leaf downward along the veins and edges, merging into long wavy yellow spots, and finally forming gray-white necrotic spots. Although more than 40 resistance genes to rice bacterial leaf blight have been discovered, not many resistance genes are actually put into production because most genes have a narrow resistance spectrum and insufficient resistance strength. Therefore, the application of chemical agents is still the main means of preventing and controlling rice bacterial leaf blight. Summary of the invention
[0005] The technical problem to be solved by the present invention is to overcome the defect of the lack of relatively effective QS system inhibitors in the prior art, and to provide the use of disulfide and its pharmaceutically acceptable salt in the prevention and / or treatment of bacterial diseases. The disulfide can strongly inhibit the quorum sensing system of pathogens without affecting the growth of some pathogens, thereby significantly reducing the pathogenicity of pathogens, that is, without affecting the growth of pathogens, the effect of treating diseases caused by pathogens is achieved. Therefore, the disulfide can be used as a quorum sensing system inhibitor of pathogenic bacteria, or prepared into a drug for related bacterial diseases, used for the prevention and / or treatment of bacterial diseases, and also has the effect of reducing and delaying the resistance of some pathogens to the compound, and has a long effective use period in the prevention and / or treatment of bacterial diseases, and has broad application prospects.
[0006] The object of the present invention is to provide disulfide having a novel structure and a pharmaceutically acceptable salt thereof.
[0007] Another object of the present invention is to provide a pathogenic bacteria inhibitor.
[0008] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0009] The present invention provides a protected disulfide and a pharmaceutically acceptable salt thereof for use in preparing a drug for preventing and / or treating bacterial diseases. The structure of the disulfide is shown in formula (I):
[0010]
[0011] In formula (I), R 1, R 2 Each independently selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl;
[0012] The R 3 It is single-substituted, multi-substituted or unsubstituted; n represents R on the benzene ring 3 The number of, n is any integer from 0 to 5; the R 3 Selected from hydrogen, C 1~6 Alkyl, -NH2, hydroxyl, -NO2 or halogen;
[0013] The R 4 is monosubstituted, polysubstituted or unsubstituted; m represents R 4 The number of, m is any integer from 0 to 6; the R 4 Selected from hydrogen, C 1~6 Alkyl, -NH2, hydroxyl, -NO2 or halogen;
[0014] And does not contain the following compounds:
[0015] In the structure represented by formula (I), the heteroaryl group is a 5-6-membered aromatic monocyclic ring or an 8-10-membered aromatic bicyclic ring, which contains 1, 2, 3 or 4 heteroatoms independently selected from N, O or S, and the remaining ring atoms are carbon;
[0016] The bacteria are selected from one or more of Pseudomonas aeruginosa, Ralstonia solanacearum, and Xanthomonas oryzae pv. oryzae (Xoo).
[0017] In response to the problem of lack of more effective QS system inhibitors in the prior art, the disulfide provided by the present invention has a strong inhibitory effect on the relevant pathogenic phenotypes of the quorum sensing system of Pseudomonas aeruginosa and the Ш-type secretion system of Ralstonia solanacearum, and the disulfide significantly reduces the pathogenicity of the pathogen without affecting the normal growth of the pathogen, thereby preventing and / or treating diseases caused by the pathogen; the disulfide has significant antibacterial activity against Xanthomonas oryzae Xoo, thereby preventing and / or treating diseases caused by the pathogen; therefore, the disulfide can be used as a pathogen quorum inhibitor, or prepared into a drug for related diseases, for the prevention and / or treatment of bacterial diseases, and also has the effect of reducing and delaying the development of drug resistance of some pathogens to the compounds, and has a longer effective service life.
[0018] Specifically, the R 3 (n) is a substituent on the benzene ring, and the H on the benzene ring is replaced by R 3 Single substitution, multiple substitution or unsubstituted; n represents R on the benzene ring 3 The number of R, n is any integer from 0 to 5; when n = 0, it means that the H on the benzene ring is not replaced; when n = 1, it means that the H on the benzene ring is replaced by R 3 Monosubstituted; when n=2-5, it means that the H on the benzene ring is replaced by R 3 Multiple substitution, R at different substitution positions 3 Same or different.
[0019] Specifically, the R 4 (m) is a substituent on a heteroaryl group, the H of the heteroaryl group is replaced by R 4 Single substitution, multiple substitution or unsubstituted; m represents R on heteroaryl 4 The number of R, m is any integer from 0 to 6; when m = 0, it means that the H on the heteroaryl is not replaced; when m = 1, it means that the H on the heteroaryl is replaced by R 3 Monosubstituted; when m=2-6, it means that the H on the heteroaryl group is replaced by R 4 Multiple substitution, R at different substitution positions 4 Same or different.
[0020] Preferably, the R 1 , R 2 Each independently selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl, and R 1 , R 2 Not selected from C 1~6 Alkyl or C3~6 Cycloalkyl;
[0021] The R 3 Selected from hydrogen, C 1~6 Alkyl, -NH2, hydroxyl, -NO2 or halogen;
[0022] The R 4 Selected from hydrogen, C 1~6 Alkyl or -NH2;
[0023] The n and m are each independently selected from any integer between 0 and 2;
[0024] In the structure represented by formula (I), the heteroaryl group is a 5- to 6-membered aromatic monocyclic ring, which contains 1, 2, 3 or 4 heteroatoms independently selected from N or S, and the remaining ring atoms are carbon.
[0025] Preferably, the R 1 , R 2 Each independently selected from C 3~6 Alkyl, C 5~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 3~6 Alkenyl or R 4 (m) substituted heteroaryl, and R 1 , R 2 Not selected from C 3~6 Alkyl or C 5~6 Cycloalkyl;
[0026] The R 3 Selected from hydrogen, C 1~3 Alkyl, -NH2, hydroxy, -NO2, fluorine, chlorine or bromine;
[0027] The R 4 Selected from hydrogen, C 1~3 Alkyl or -NH2.
[0028] More preferably, the disulfide is selected from any of the following structures:
[0029]
[0030] Furthermore, the disulfide and pharmaceutically acceptable salts thereof inhibit the production of bacterial pathogenicity factors and / or virulence factors.
[0031] Furthermore, the disulfide and its pharmaceutically acceptable salt inhibit the production of pyocyanin and elastase and the clustering movement of Pseudomonas aeruginosa; the disulfide and its pharmaceutically acceptable salt inhibit the motility of Ralstonia solanacearum; the disulfide and its pharmaceutically acceptable salt inhibit the growth of Xanthomonas oryzae.
[0032] The present invention also protects disulfide and pharmaceutically acceptable salts thereof, wherein the structure of the disulfide is shown in formula (II):
[0033]
[0034] In formula (II), R 1 , R 2 Each independently selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl; and R 1 , R 2 Not selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl;
[0035] The R 3 It is single-substituted, multi-substituted or unsubstituted; n represents R on the benzene ring 3 The number of, n is any integer from 0 to 5; the R 3 Selected from hydrogen, C 1~6 Alkyl, -NH2, hydroxyl, -NO2 or halogen;
[0036] The R 4 is monosubstituted, polysubstituted or unsubstituted; m represents R 4 The number of, m is any integer from 0 to 6; the R 4 Selected from hydrogen, C 1~6 Alkyl, -NH2, hydroxyl, -NO2 or halogen;
[0037] And does not contain the following compounds:
[0038]
[0039] In the structure represented by formula (II), the heteroaryl group is a 5-6 membered aromatic monocyclic ring or an 8-10 membered aromatic bicyclic ring, which contains 1, 2, 3 or 4 heteroatoms independently selected from N, O or S, and the remaining ring atoms are carbon.
[0040] Specifically, in the structure shown in formula (II), the R 3 (n) is a substituent on the benzene ring, and the H on the benzene ring is replaced by R 3Single substitution, multiple substitution or unsubstituted; n represents R on the benzene ring 3 The number of R, n is any integer from 0 to 5; when n = 0, it means that the H on the benzene ring is not replaced; when n = 1, it means that the H on the benzene ring is replaced by R 3 Monosubstituted; when n=2-5, it means that the H on the benzene ring is replaced by R 3 Multiple substitution, R at different substitution positions 3 Same or different;
[0041] Specifically, in the structure shown in formula (II), the R 4 (m) is a substituent on a heteroaryl group, the H of the heteroaryl group is replaced by R 4 Single substitution, multiple substitution or unsubstituted; m represents R on heteroaryl 4 The number of R, m is any integer from 0 to 6; when m = 0, it means that the H on the heteroaryl is not replaced; when m = 1, it means that the H on the heteroaryl is replaced by R 3 Monosubstituted; when m=2-6, it means that the H on the heteroaryl group is replaced by R 4 Multiple substitution, R at different substitution positions 4 Same or different.
[0042] Preferably, the R 1 , R 2 Each independently selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl; and R 1 , R 2 Not selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl;
[0043] The R 3 Selected from hydrogen, C 1~3 Alkyl, -NH2, hydroxy, -NO2, fluorine, chlorine or bromine;
[0044] The R 4 Selected from hydrogen, C 1~3 Alkyl or -NH2.
[0045] The n and m are both selected from any integer from 0 to 2;
[0046] In the structure represented by formula (II), the heteroaryl group is a 5- to 6-membered aromatic monocyclic ring, which contains 1, 2, 3 or 4 heteroatoms independently selected from N or S, and the remaining ring atoms are carbon.
[0047] Preferably, the R 1 , R 2 Each independently selected from C 3~6 Alkyl, C 5~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 3~6 Alkenyl or R 4 (m) substituted heteroaryl, and R 1 , R 2 Not selected from C 3~6 Alkyl, C 5~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 3~6 Alkenyl or R 4 (m) substituted heteroaryl;
[0048] The R 3 is selected from hydrogen or hydroxyl;
[0049] The R 4 Selected from hydrogen.
[0050] More preferably, the disulfide is selected from any of the following structures:
[0051]
[0052] Furthermore, the preparation method of the disulfide having a novel structure comprises the following steps: replacing the thiol R 1 -SH and substituted thiol R 2 -SH reacts in the presence of a diluent and a catalyst to prepare a compound represented by formula (II), wherein R 1 and R 2 The definition of is consistent with R1 and R2 in the structure of formula (II).
[0053] Preferably, the mercaptan is reacted in the presence of a diluent and a catalyst at a reaction temperature of 0 to 120° C. As a more preferred embodiment, the reaction temperature is 20 to 60° C.
[0054] Preferably, the reaction time is 1 to 24 hours.
[0055] More preferably, the reaction time is 6 to 12 hours.
[0056] Preferably, the substituted thiol R 1 -SH and substituted thiol R 2The molar ratio of the combination of -SH, diluent and catalyst is (0.5~5):(50~300):(0.5~3).
[0057] More preferably, the molar ratio of the mercaptan, the diluent and the catalyst is (1-2):(150-200):(0.5-2).
[0058] Preferably, the diluent is an inert organic solvent.
[0059] More preferably, the diluent is at least one of hexane, cyclohexane, dichloromethane, chloroform, carbon tetrachloride, methanol, ethanol, n-propanol, isopropanol, acetone, butanone, methyl isobutyl ketone, acetonitrile, propionitrile, butyronitrile, benzene, toluene, xylene, chlorobenzene, dichlorobenzene, methyl acetate, ethyl acetate, dimethyl sulfoxide, dioxane, tetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-formanilide, N-methylpyrrolidone, hexamethylphosphoric triamide, petroleum ether, ethyl ether, diisopropyl ether, ethylene glycol monomethyl ether, ethylene glycol dimethyl ether, ethylene glycol monoethyl ether, ethylene glycol diethyl ether, diethylene glycol monomethyl ether and diethylene glycol monoethyl ether.
[0060] More preferably, the diluent is at least one of acetonitrile, tetrahydrofuran or dichloromethane.
[0061] Preferably, the catalyst is one of sodium hydroxide, potassium carbonate, 2,3-dichloro-5,6-dicyanobenzoquinone, triethylamine, pyridine, bromine water, dibromohydantoin, N,N-dimethylaniline, N,N-dimethylformamide, N-methylpiperidine, N-methylmorpholine, and N,N-dimethylaminopyridine.
[0062] More preferably, the catalyst is one of potassium carbonate, 2,3-dichloro-5,6-dicyanobenzoquinone, bromine water, N,N-dimethylformamide and dibromohydantoin.
[0063] The present invention also protects a pathogenic bacteria inhibitor, comprising the disulfide or a pharmaceutically acceptable salt thereof.
[0064] Furthermore, the pathogenic bacteria inhibitor is in the form of powder, granules, water-dispersible granules, suspension, emulsifiable concentrate, microemulsion or aqueous solution.
[0065] Compared with the prior art, the present invention has the following beneficial effects: the disulfide of the present invention has a strong inhibitory effect on the relevant pathogenic phenotypes of the quorum sensing system of Pseudomonas aeruginosa and the Ш-type secretion system of Ralstonia solanacearum, and the effect is even better than that of the positive control drug diallyl disulfide, and at the same time does not affect the normal growth of the above two pathogens, that is, the compound significantly reduces the pathogenicity of the pathogen without affecting the growth of the pathogen, thereby achieving the prevention and / or treatment of diseases caused by the pathogen; the disulfide has significant antibacterial activity against Xanthomonas oryzae Xoo, thereby achieving the prevention and / or treatment of diseases caused by the pathogen; therefore, the disulfide can be used as a pathogen population inhibitor, or prepared into a drug for related bacterial diseases, for the prevention and / or treatment of bacterial diseases, and at the same time has the effect of reducing and delaying the development of drug resistance of some pathogens to the compound, has a long effective use period in the prevention and / or treatment of diseases, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0066] Figure 1 Schematic diagram of the structures of disulfide compounds and their corresponding numbers.
[0067] Figure 2 Statistical graph of data from high-throughput screening of disulfide using a Pseudomonas aeruginosa reporter strain.
[0068] Figure 3 This graph shows the effect of disulfide inhibitors on the growth of P. aeruginosa PAO1.
[0069] Figure 4 Statistical graph showing the effects of disulfide inhibitors on virulence factors of P. aeruginosa PAO1.
[0070] Figure 5 This is a statistical graph showing the effects of disulfide on the expression of genes related to the quorum sensing system of P. aeruginosa PAO1.
[0071] Figure 6 This is a statistical graph of the data for high-throughput screening of disulfide using a Ralstonia solanacearum reporter strain.
[0072] Figure 7 The effect of disulfide inhibitors on the growth of Ralstonia solanacearum
[0073] Figure 8 This is a statistical diagram of the effect of disulfide on the swimming motility of Ralstonia solanacearum.
[0074] Fig. 9 This is a statistical graph of the qRT-PCR detection of disulfide-related genes of Ralstonia solanacearum.
[0075] Fig.10 The appearance of the effect of Ralstonia solanacearum on host tomatoes under disulfide treatment conditions (a~b) and the statistical data of the degree of wilting (c).
[0076] Fig.11 These are SEM images of the cell membrane morphology of Xoo after treatment with disulfide 2e at different concentrations, where a is the SEM image of the bacteria treated with DMSO, b is the SEM image of the bacteria treated with 25 mg / mL compound 2e, c is the SEM image of the bacteria treated with 50 mg / mL compound 2e, and d is the SEM image of the bacteria treated with 100 mg / mL compound 2e. DETAILED DESCRIPTION
[0077] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0078] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0079] The following examples are for testing the virulence inhibition of Pseudomonas aeruginosa, Ralstonia solanacearum, Xanthomonas oryzae pv. oryzae (Xoo) and the growth inhibition of Xanthomonas oryzae pv. oryzae (Xoo). The test compounds were dissolved in DMSO, and DMSO was used as the solvent control in the experiment.
[0080] The transcriptional reporter plasmids containing rhlA-gfp, pqsA-gfp, and lasB-gfp were respectively transformed into Pseudomonas aeruginosa to obtain reporter strains PAO1-rhlA-gfp, PAO1-pqsA-gfp, and PAO1-lasB-gfp. (J. Fong, M. Yuan, TH Jakobsen, KTM Mortensen, MMS Delos Santos, SL C Hua, L. Yang, CH Tan, TE Nielsen, M. Givskov, Disulfide Bond-Containing Ajoene Analogues as NovelQuorum Sensing Inhibitors of Pseudomonas aeruginosa, J Med Chem 60 (2017) 215–227. https: / / doi.org / 10.1021 / acs.jmedchem.6b01025)
[0081] Example 1 Synthesis of Compound 4e
[0082] The structure of the compound 2-(pentyldithio)thiazole 4e is shown below, and its synthesis method comprises the following steps:
[0083]
[0084] Thiothiazole (1.0mmol) and pentanethiol (1.5mmol) were dissolved in 10mL DCM. Then 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (1.0mmol) was slowly added to the solution, and the reaction mixture was stirred at room temperature for 6h. The progress of the reaction was monitored by TLC. After the reaction was completed, the insoluble matter was removed by filtration, and the filtrate was concentrated by rotary evaporation. The crude compound was purified by silica gel column chromatography (with petroleum ether and ethyl acetate as eluents) to obtain compound 4e.
[0085] Example 2 Synthesis of Compound 7e
[0086] The structure of the compound (4-hydroxyphenyl)pentane disulfide 7e is shown below, and its synthesis method comprises the following steps:
[0087]
[0088] p-Hydroxybenzenethiol (1.0mmol), pentanethiol (1.5mmol) and potassium carbonate (1.0mmol) were dissolved in 10mL acetonitrile and stirred at room temperature for 12h. After TLC monitoring, the insoluble matter was filtered off and the acetonitrile was evaporated under reduced pressure. 50mL ethyl acetate was extracted, washed with water (50mL) twice, the organic layer was combined, dried over anhydrous Na2SO4, and concentrated by evaporation under reduced pressure. The residue was chromatographed on a silica gel column (eluent was petroleum ether and ethyl acetate) to obtain compound 7e.
[0089] According to the method of Example 1 and Example 2, only R1 and R2 in the compound represented by formula (I) are Figure 1 Replace as shown to obtain the corresponding product of formula (I). The specific structure of the product is shown in Figure 1 The physical and chemical properties, nuclear magnetic resonance mass spectrum and hydrogen spectrum detection results of the above disulfide with novel structure are listed in Table 1 and Table 2:
[0090]
[0091] Table 1 Physicochemical properties of disulfides with novel structures
[0092]
[0093]
[0094] Table 2 H NMR data of disulfide with novel structure
[0095]
[0096]
[0097]
[0098] Example 3 Screening of quorum sensing inhibitors
[0099] Methods: The reporter strain PAO1-lasB-gfp was streaked on LB (Luria Bertani, referred to as LB medium) solid medium containing 50μg / mL gentamicin (GM), cultured at 37°C for 12 hours, and stored in a 4°C refrigerator after a single colony grew out for use. Pick a single colony and inoculate it into ABTGC medium containing 50μg / mL GM and culture it for 12 hours until the logarithmic phase. Centrifuge at 4°C, 7000rpm for 3min, collect the bacteria and wash them with phosphate buffered saline (PBS). Add ABTGC medium to resuspend and dilute to an optical density (OD) of 0.02 at 600nm. Mix the target compound with the diluted bacterial solution to a final concentration of 80μg / mL. Culture in a shaker at 220rpm, 37°C for 12 hours, and use a microplate reader to measure the cell density (OD) of the bacterial solution. 600 ) and the mean fluorescence intensity (MFI) of green fluorescent protein (GFP) (excitation wavelength is 485nm, emission wavelength is 535nm), record the data and calculate the inhibition rate of the target compound on the reporter strain. The specific calculation method is: inhibition rate % = 100% - [MFI (drug-added group) / OD 600 (drug-added group)] / [MFI(DMSO) / OD 600 (DMSO)].
[0100] The experimental scheme of reporter strains PAO1-rhlA-gfp and PAO1-pqsA-gfp is consistent with that of PAO1-lasB-gfp. lasB, rhlA and pqsA are the key genes of the three QS systems of Pseudomonas aeruginosa and are also the most upstream promoters. These sites have been confirmed in publicly published studies. Figure 2 The diallyl disulfide (DADS) marked in the figure is the positive control group, DMSO is the solvent control group, and the rest are test groups of different compounds. If the test compound has a high inhibitory activity (close to or better than the positive control) against any two of the three reported strains, it means that the compound has a strong inhibitory activity.
[0101] Depend on Figure 2It can be seen that most of the disulfide compounds listed have a strong inhibition rate against the above-mentioned reported strains, such as the known compounds 2e, 2h, 2i, 2j, 2k, 2l, 2m, 2o, 2r, 3a, 3d, 3e, 3i, 4a-c, 4f, 4h, 6a, 6c, 6f, 6g, 6h, 7a-7c, 9h, 10a-10c and compounds with novel structures 4e, 4g, 5a-5h, 6b, 6e, 7e-7g, 8a-8h, 9a-9g, 10d-10f. Among them, compounds 2i and 10d have the best inhibitory activity, so the subsequent experiments selected disulfide 2i and 10d as representative compounds for exploration.
[0102] Example 4 Effects of disulfides 2i and 10d on the growth of PAO1
[0103] Pseudomonas aeruginosa PAO1 wild type was streaked on LB solid medium and cultured at 37°C for 12 hours. After a single colony grew, it was placed in a 4°C refrigerator for later use. A single colony was picked and inoculated into LB medium and cultured for 12 hours until the logarithmic phase. Centrifuged at 4°C, 7000 rpm for 3 minutes, the cells were collected and washed with PBS. Resuspended in LB medium and adjusted the OD 600 To 0.1. Compounds 2i and 10d were mixed with the diluted bacterial solution to a final concentration of 80 μg / mL. The test compound was replaced with DADS as a positive control, and only DMSO was added as a solvent control group. No other reagents were added as a blank control (WT group). 200 μL of bacterial solution was injected into each well of a 100-well plate dedicated to growth curve measurement. The treated plate was placed in an automatic growth curve instrument and cultured at 37°C under continuous shaking for 48 hours, and the OD was measured every hour. 600 value.
[0104] The results are as follows Figure 3 As shown, the growth curves of the bacteria after adding disulfide for 2i and 10d were basically the same as those of the WT group and the DMSO group, indicating that disulfide for 2i and 10d had no effect on the growth of PAO1.
[0105] Example 5 Effects of disulfide on virulence factors of P. aeruginosa PAO1
[0106] In order to detect the effect of disulfide on the quorum sensing system of Pseudomonas aeruginosa PAO1, the content of pyocyanin regulated by the rhl system and pqs system and protease regulated by the las system were detected. Pyocyanin and total protease are both important virulence factors of Pseudomonas aeruginosa.
[0107] (1) Determination of pyocyanin production
[0108] A single wild-type PAO1 colony was selected and inoculated into LB medium and cultured for 12 h until the logarithmic phase. The OD was adjusted using PB medium. 600 The target compound was mixed with the diluted bacterial solution to a final concentration of 80 μg / mL. The mixture was incubated at 37°C and 220 rpm for 24 h, and the OD value was measured. 600 Centrifuge at 5000rpm for 3min, take the supernatant and mix it with an equal volume of chloroform, shake well and centrifuge to obtain the chloroform layer. Add 0.2mol / L hydrochloric acid to acidify and measure OD 695 Value. By OD 695 Divide the value by OD 600 The data were normalized and statistically analyzed.
[0109] (2) Determination of elastase production
[0110] A single wild-type PAO1 colony was selected and inoculated into LB medium and cultured for 12 h until the logarithmic phase. The OD was adjusted by LB medium. 600 The target compound was mixed with the diluted bacterial solution to a final concentration of 80 μg / mL. The mixture was incubated at 37°C and 220 rpm for 24 h, and the OD value was measured. 600 Value. Centrifuge at 12,000 rpm for 15 min at 4°C, take 500 μL of supernatant and add 5 mg / mL Elastin-Congo red (ECR) buffer, and incubate at 37°C for 2 h. Add 0.12 mM EDTA to terminate the reaction, and centrifuge at 4°C and 5000 rpm to remove ECR. Add 200 μL of supernatant to a 96-well plate and use an ELISA reader to measure OD 495 Value. By OD 495 Divide the value by OD 600 The data were normalized and statistically analyzed.
[0111] The results are as follows Figure 4 As shown, disulfide 2i and 10d can significantly inhibit the activity of pyocyanin and elastase. Therefore, disulfide exhibits a certain inhibitory effect on the RHL system, PQS system and LAS system of Pseudomonas aeruginosa, thereby inhibiting the production of virulence factors.
[0112] Example 6 Effects of disulfide on the expression of genes related to the quorum sensing system of P. aeruginosa PAO1
[0113] In order to further clarify the mechanism of disulfide inhibition of Pseudomonas aeruginosa PAO1 quorum sensing system, qRT-PCR was used to detect its effect on the expression of genes related to the PAO1 quorum sensing system. The lasA, lasB, lasI, lasR, pqsA, pqsR, rhlI and rhlR genes play an important role in the QS system of Pseudomonas aeruginosa, and their own expression is also regulated by the QS system. Among them, lasA encodes LasA protease, and lasB encodes elastase. The mature protease is secreted into the extracellular space to degrade the host cell extracellular matrix and decompose immune molecules, playing an important role in the infection process of Pseudomonas aeruginosa; the LasI / LasR system regulates the expression of various virulence factors involved in the pathogenesis of acute infection, including exotoxin A and alkaline protease, and also affects the formation of flagella and pili, thereby affecting the motility of Pseudomonas aeruginosa. The rhl system is responsible for regulating the expression of rhamnolipids and is involved in the release of Pseudomonas aeruginosa toxin proteins into the cytoplasm of host cells; the pqs system induces the production of rhamnolipids and other molecules involved in the formation of Pseudomonas aeruginosa biofilms. The transcription factor ropD was used as an internal reference gene to quantify the relative expression of this target gene. The expression fold change between the treatment group and the control group was expressed as 2 -△△Ct method to calculate.
[0114] The results are as follows Figure 5 As shown, the expression of genes was significantly decreased after 2i and 10d of treatment with disulfide, indicating that disulfide inhibits the expression of quorum sensing-related genes.
[0115] Example 7 Screening of T3SS inhibitors
[0116] Incubate the reporter strain PhrpY-lux in BG medium (final concentration of Gm is 30 μg / mL) overnight until the growth logarithmic phase. Centrifuge at 4000 r / min for 10 min, discard the supernatant, add an equal volume of MM (Minimal Medium) medium (containing 20 mM sodium glutamate) to suspend the cells, and adjust the OD 600 To 0.3. Each sample was dispensed with 500 μL of the stock solution, and the test compound was added to a final concentration of 100 μmol / L, DMSO was used as a solvent control, and 2,3,4-trihydroxybenzylidenebenzohydrazide (SA1) was used as a positive control. After adding the test compound, 150 μL of each sample was dispensed into a 96-well plate in triplicate. After incubation at 220 r / min, 28°C on a shaker for 8 hours, the luminescence and absorbance of the sample were measured with an ELISA reader, and the data were recorded and processed. The experiment was repeated more than three times independently.
[0117] In order to detect and quantify the inhibitory effects of the optimized compounds, this study used the lux reporter system for rescreening of T3SS inhibitors. The specific operations are as follows: First, the promoter of the hrpY gene (PhrpY) was fused with the plasmid carrying the luxCDABE reporter gene by PCR to construct the target vector pPhrpY. Then, the vector was integrated into the genome of R. solanacearum GMI1000 to obtain a reporter strain containing the pPhrpY vector so that the expression level of the hrpY gene could be evaluated by detecting the fluorescence level. Next, the GMI1000 strain carrying the pPhrpY vector was grown in a medium that induced hrpY expression, and the fluorescence intensity was measured after incubation with each compound for 8 hours. To normalize the data, the fluorescence intensity will be calculated according to the cell density (OD 600 ) to make adjustments. This can effectively evaluate the effect of compounds on T3SS activity and further screen out compounds with significant inhibitory effects. The specific algorithm is:
[0118]
[0119] The results are as follows Figure 6 As shown, compounds 2e, 2g, 2i, 2r, 3a, 3b, and 3e all had significant inhibitory effects on T3SS activity, among which disulfide 2e showed the best inhibitory activity.
[0120] Example 8 Effect of disulfide on the growth of Ralstonia solanacearum
[0121] GMI1000 strain was cultured overnight in BG medium until the logarithmic phase of growth. Centrifuged at 4000r / min for 10min, discarded the supernatant, and added an equal volume of MM medium (containing 20mM sodium glutamate) and BG medium to suspend the bacteria to ensure normal growth of the strain. Dilution OD 600 The final concentration of the compound was 100 μmol / L, DMSO was used as the solvent control, and WT was used as the blank control. 300 μL of the mixed solution was added to the growth curve plate and measured at 30°C for 72 hours.
[0122] The results are as follows Figure 7 As shown, the growth curve of the bacteria after adding disulfide 2e was basically the same as that of the WT group and the DMSO group, indicating that disulfide 2e had no effect on the growth of Ralstonia solanacearum.
[0123] Example 9 Effect of disulfide on swimming motility of Ralstonia solanacearum
[0124] First prepare a BG solid medium containing 0.3% agar powder. Culture the Ralstonia solanacearum GMI1000 strain (wild type, WT) in BG medium overnight. The final concentration of the compound is 100 μmol / L, WT is the blank control, and DMSO is the solvent control. After the Swimming solid medium is sterilized by high pressure, pour it evenly into a square culture dish after it cools down and is not hot to the touch. After the medium is allowed to solidify, take 2 μL of the bacterial solution and gently spot it in the designated area. After spotting, wait for the bacterial solution to dry and invert it in a 28°C constant temperature incubator for 2-3 days. Take out the plate to observe the swimming situation and take photos to record.
[0125] The results are as follows Figure 8 As shown, the motility of Ralstonia solanacearum was significantly reduced after treatment with disulfide 2e.
[0126] Example 10 qRT-PCR detection of pathogenicity-related genes of Ralstonia solanacearum by disulfide
[0127] The Ralstonia solanacearum GMI1000 strain was cultured in BG medium overnight. On the next day, the bacteria were centrifuged at 4000r / min for 10 minutes. After the bacteria were collected, they were suspended in an equal volume of MM medium (containing 20mM sodium glutamate) with a final concentration of 100μmol / L. The culture was continued at 220r / min and 28°C in a shaking incubator for 8h. After the specified time, the bacteria were centrifuged at 4000r / min for 10 minutes and collected. RNA was extracted using the imported Tiangen Promega RNA extraction kit. During the extraction process, measures must be taken to avoid RNA degradation and contamination; the temperature must be maintained at 4°C during centrifugation. The integrity and quality of RNA were judged by gel electrophoresis experiments and RNA concentration. High-concentration, high-quality and high-purity RNA was reverse transcribed using the Tiangen reverse kit and retrograde system to obtain cDNA. The cDNA level was quantified using SYBR Green real-time PCR. The gyrA gene was used as the internal reference gene in this experiment, and 2 -ΔΔCt The relative expression level of the target gene was quantified.
[0128] The results are as follows Fig. 9 As shown, after treatment with disulfide 2e, the expression of most genes related to T3SS decreased significantly, indicating that disulfide compounds inhibit the expression of T3SS-related genes of Ralstonia solanacearum.
[0129] Example 11 Pathogenicity test of Ralstonia solanacearum on host tomatoes under disulfide treatment conditions
[0130] Culture the Ralstonia solanacearum GMI1000 strain in BG medium overnight. The next day, transfer 2%-4% of the cells to fresh BG medium and continue culturing until the logarithmic phase. Resuspend the cells in ddH2O and adjust the OD 600 to 0.3(10 8CFU / mL), add the compound to a final concentration of 100μmol / L. Next, use a scalpel to injure two places on both sides of the root of each 4-week-old tomato plant (Solanumlycopersicum cv. Moneymaker), and then slowly inject the soil containing bacteria or a mixture of bacterial solution and compounds with a 5mL pipette, 5mL on each side, a total of 10mL. The inoculated plants are placed in a pre-programmed light incubator and continue to be cultured, waiting for the wild-type plants to become ill (symptoms of bacterial wilt wilt appear). 7-17 plants are used under each condition, and the wilting symptoms of each plant are recorded, and the semi-quantitative wilting grade is evaluated from 0 (no wilting) to 4 (death), corresponding to the percentage of different leaf wilting degrees (0%, 25%, 50%, 75% or 100%). Finally, when all the wild-type plants without the addition of the compound become ill, the disease recording is stopped and photos are taken.
[0131] The results are as follows Fig.10 As shown in the figure, compared with the group without drug addition, the pathogenicity of Ralstonia solanacearum was significantly inhibited after treatment with disulfide 2e, and the degree of plant wilting was significantly reduced ( Fig.10 a~b), the severity of the disease is directly reduced from level 4 to below level 1 ( Fig.10 c) in.
[0132] Example 12 Testing of the Minimum Inhibitory Concentration (MIC) of Disulfide Compounds against Xoo
[0133] Xanthomonas oryzae pv.oryzae (Xoo) cultured overnight in LB liquid culture medium, mixed; 196 μL of the above mixture was added to each well of a 96-well bacterial culture plate using a spray gun; 4 μL of gradient diluted compounds were added to make the concentration gradient 3.125, 6.25, 12.5, 25, 50, 100 and 200 μg / mL; an equal volume of DMSO was used as a solvent control, and BMT (chlorothiazol) was used as a positive control, and three replicates were used; the results were observed after static culture at 28°C for 24 hours. The lowest drug concentration that significantly inhibits microbial growth within the range visible to the naked eye and the bacterial solution remains clear without turbidity is the MIC.
[0134] Table 3 Results of determination of minimum inhibitory concentration of disulfide compounds against Xoo
[0135]
[0136] Note: MIC (μg / mL)>50 indicates no significant inhibitory activity.
[0137] The results are shown in Table 3. Disulfide 2e, 2h, 2i, 2j, 2k, 2l, 2t, 3a, 3e, and 3i all have good inhibitory activity against the above Xoo, among which disulfide 2e shows the best inhibitory activity. Therefore, disulfide 2e was used as a representative compound for testing in subsequent experiments.
[0138] Example 13 Testing the Effect of Disulfide Compounds on Xoo Cell Membrane Morphology and Apoptosis Level Determination
[0139] Morphological changes are an important way to evaluate the effects of compounds on bacteria. Scanning electron microscopy (SEM) and Annexin V-FITC / PI apoptosis kit were used to observe the surface morphology and apoptosis level of bacteria after compound treatment. SEM sample processing: The bacterial solution was cultured to OD 600 =0.8, then add the compound to adjust the concentration to 25mg / mL, 50mg / mL, 100mg / mL, and add an equal amount of DMSO to the negative control. After shaking for 12h, the bacteria were collected by centrifugation and fixed with 2.5% glutaraldehyde at 4℃ overnight and osmium acid for 2h. Before each fixation, they were washed 3 times with PBS, each time for 10min. The fixed slides were dried and plated. The level of cell apoptosis depends on the degree of membrane depolarization. According to the instructions of the kit, the concentration of the bacterial suspension was adjusted to 10 6 CFU / mL, the compound concentration was consistent with SEM. After shaking culture for 16 h, the cells were washed twice with PBS and resuspended in an equal volume of Binding Buffer. 5 μL Annexin V-FITC and 10 μL propidium iodide (PI) were added to 100 μL bacterial suspension. After incubation in the dark for 15 min, the level of cell apoptosis was detected by flow cytometry.
[0140] The results are as follows Fig.11 As shown, disulfide 2e caused obvious lysis of bacteria, and was drug concentration-dependent. The higher the experimental concentration, the more obvious the lysis degree.
[0141] In summary, the above examples illustrate that the disulfide compounds of the present invention play a role in preventing and / or treating diseases caused by pathogenic bacteria, indicating that disulfide has inhibitory activity against the quorum sensing system of Pseudomonas aeruginosa PAO1 and the Ш-type secretion system of Ralstonia solanacearum. Disulfide can be used to inhibit the virulence system of Pseudomonas aeruginosa and Ralstonia solanacearum, reduce the production of their virulence factors, and reduce the production of drug resistance in pathogens, thereby extending the service life of the drug. The disulfide of the present invention has significant bactericidal activity against Xanthomonas oryzae Xoo, achieving the purpose of preventing and / or treating diseases caused by pathogenic bacteria.
[0142] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. Use of disulfide and pharmaceutically acceptable salts thereof in the preparation of drugs for preventing and / or treating bacterial diseases, characterized in that: The structure of the disulfide is shown in formula (I): In formula (I), R 1 , R 2 Each independently selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl; The R 3 It is single-substituted, multi-substituted or unsubstituted; n represents R on the benzene ring 3 The number of, n is any integer from 0 to 5; the R 3 Selected from hydrogen, C 1~6 Alkyl, -NH2, hydroxyl, -NO2 or halogen; The R 4 is monosubstituted, polysubstituted or unsubstituted; m represents R 4 The number of, m is any integer from 0 to 6; the R 4 Selected from hydrogen, C 1~6 Alkyl, -NH2, hydroxyl, -NO2 or halogen; And does not contain the following compounds: In the structure represented by formula (I), the heteroaryl group is a 5-6-membered aromatic monocyclic ring or an 8-10-membered aromatic bicyclic ring, which contains 1, 2, 3 or 4 heteroatoms independently selected from N, O or S, and the remaining ring atoms are carbon; The bacteria are selected from one or more of Pseudomonas aeruginosa, Ralstonia solanacearum, and Xanthomonas oryzae pv. oryzae.
2. The application according to claim 1, characterized in that: The R 1 , R 2 Each independently selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl, and R 1 , R 2 Not selected from C 1~6 Alkyl or C 3~6 Cycloalkyl; The R 3 Selected from hydrogen, C 1~6 Alkyl, -NH2, hydroxyl, -NO2 or halogen; The R 4 Selected from hydrogen, C 1~6 Alkyl or -NH2; The n and m are each independently selected from any integer between 0 and 2; In the structure represented by formula (I), the heteroaryl group is a 5- to 6-membered aromatic monocyclic ring, which contains 1, 2, 3 or 4 heteroatoms independently selected from N or S, and the remaining ring atoms are carbon.
3. The application according to claim 2, characterized in that: The R 1 , R 2 Each independently selected from C 3~6 Alkyl, C 5~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 3~6 Alkenyl or R 4 (m) substituted heteroaryl, and R 1 , R 2 Not selected from C 3~6 Alkyl or C 5~6 Cycloalkyl; The R 3 Selected from hydrogen, C 1~3 Alkyl, -NH2, hydroxy, -NO2, fluorine, chlorine or bromine; The R 4 Selected from hydrogen, C 1~3 Alkyl or -NH2.
4. The use according to claim 3, characterized in that: The disulfide is selected from any of the following structures:
5. Disulfide and pharmaceutically acceptable salts thereof, characterized in that: The structure of the disulfide is shown in formula (II): In formula (II), R 1 , R 2 Each independently selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl; and R 1 , R 2 Not selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl; The R 3 It is single-substituted, multi-substituted or unsubstituted; n represents R on the benzene ring 3 The number of, n is any integer from 0 to 5; the R 3 Selected from hydrogen, C 1~6 Alkyl, -NH2, hydroxyl, -NO2 or halogen; The R 4 is monosubstituted, polysubstituted or unsubstituted; m represents R 4 The number of, m is any integer from 0 to 6; the R 4 Selected from hydrogen, C 1~6 Alkyl, -NH2, hydroxyl, -NO2 or halogen; And does not contain the following compounds: In the structure represented by formula (II), the heteroaryl group is a 5-6 membered aromatic monocyclic ring or an 8-10 membered aromatic bicyclic ring, which contains 1, 2, 3 or 4 heteroatoms independently selected from N, O or S, and the remaining ring atoms are carbon.
6. The disulfide and pharmaceutically acceptable salt thereof according to claim 5, characterized in that: The R 1 , R 2 Each independently selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl; and R 1 , R 2 Not selected from C 1~6 Alkyl, C 3~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 2~6 Alkenyl or R 4 (m) substituted heteroaryl; The R 3 Selected from hydrogen, C 1~3 Alkyl, -NH2, hydroxy, -NO2, fluorine, chlorine or bromine; The R 4 Selected from hydrogen, C 1~3 Alkyl or -NH2. The n and m are both selected from any integer from 0 to 2; In the structure represented by formula (II), the heteroaryl group is a 5- to 6-membered aromatic monocyclic ring, which contains 1, 2, 3 or 4 heteroatoms independently selected from N or S, and the remaining ring atoms are carbon.
7. The disulfide and pharmaceutically acceptable salt thereof according to claim 6, characterized in that: The R 1 , R 2 Each independently selected from C 3~6 Alkyl, C 5~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 3~6 Alkenyl or R 4 (m) substituted heteroaryl, and R 1 , R 2 Not selected from C 3~6 Alkyl, C 5~6 Cycloalkyl, R 3 (n) Substituted benzene ring, C 3~6 Alkenyl or R 4 (m) substituted heteroaryl; The R 3 is selected from hydrogen or hydroxyl; The R 4 Selected from hydrogen.
8. The disulfide and pharmaceutically acceptable salt thereof according to claim 7, characterized in that: The disulfide is selected from any of the following structures:
9. A pathogenic bacteria inhibitor, characterized in that: It comprises the disulfide according to any one of claims 5 to 8 or a pharmaceutically acceptable salt thereof.
10. The pathogenic bacteria inhibitor according to claim 9, characterized in that: The dosage form of the pathogenic bacteria inhibitor is powder, granule, water dispersible granule, suspension, emulsifiable concentrate, microemulsion or aqueous solution.
